X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11052) 11052
Magazine Article (34) 34
Newsletter (12) 12
Book Chapter (6) 6
Dissertation (6) 6
Book Review (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9329) 9329
male (6152) 6152
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (5229) 5229
female (5103) 5103
statins (4672) 4672
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (4244) 4244
middle aged (4004) 4004
aged (3391) 3391
animals (2562) 2562
cholesterol (2283) 2283
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (2164) 2164
risk factors (2146) 2146
simvastatin (2115) 2115
pharmacology & pharmacy (2070) 2070
cardiac & cardiovascular systems (2062) 2062
treatment outcome (2038) 2038
atorvastatin (2013) 2013
adult (2000) 2000
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (1949) 1949
cholesterol, ldl - blood (1414) 1414
risk (1323) 1323
prevention (1234) 1234
atorvastatin calcium (1228) 1228
dose-response relationship, drug (1195) 1195
therapy (1185) 1185
medicine, general & internal (1178) 1178
pravastatin (1170) 1170
hypercholesterolemia - drug therapy (1143) 1143
abridged index medicus (1113) 1113
drug therapy, combination (1099) 1099
drug therapy (1088) 1088
atherosclerosis (1078) 1078
rats (1073) 1073
cardiovascular diseases - prevention & control (1065) 1065
lipids (1023) 1023
dosage and administration (1014) 1014
analysis (1013) 1013
statin (1000) 1000
research (990) 990
care and treatment (981) 981
time factors (975) 975
cardiovascular disease (962) 962
aged, 80 and over (946) 946
mortality (946) 946
peripheral vascular disease (935) 935
cardiovascular (886) 886
coronary-heart-disease (878) 878
cardiovascular diseases (865) 865
retrospective studies (851) 851
cholesterol - blood (847) 847
hypercholesterolemia (846) 846
heptanoic acids - administration & dosage (778) 778
rosuvastatin (776) 776
pyrroles - administration & dosage (773) 773
disease (767) 767
prospective studies (743) 743
simvastatin - administration & dosage (739) 739
anticholesteremic agents - therapeutic use (728) 728
inflammation (728) 728
antilipemic agents (724) 724
health aspects (715) 715
rosuvastatin calcium (713) 713
follow-up studies (708) 708
medicine & public health (706) 706
mice (693) 693
cardiovascular agents (687) 687
double-blind method (685) 685
c-reactive protein (664) 664
hydroxymethylglutaryl-coa reductase inhibitors (650) 650
internal medicine (637) 637
lipids - blood (634) 634
cardiovascular-disease (631) 631
anticholesteremic agents - administration & dosage (630) 630
myocardial-infarction (630) 630
metaanalysis (624) 624
simvastatin - therapeutic use (620) 620
dyslipidemias - drug therapy (615) 615
heptanoic acids - therapeutic use (607) 607
pyrroles - therapeutic use (603) 603
risk assessment (603) 603
cardiology (600) 600
randomized controlled trials as topic (600) 600
drug interactions (597) 597
safety (567) 567
hyperlipidemias - drug therapy (566) 566
diabetes (565) 565
efficacy (559) 559
low density lipoproteins (556) 556
statin therapy (552) 552
triglycerides - blood (547) 547
coa reductase inhibitors (546) 546
lovastatin (537) 537
biomarkers - blood (532) 532
simvastatin - pharmacology (531) 531
drug administration schedule (528) 528
coronary heart disease (526) 526
cholesterol, hdl - blood (523) 523
disease models, animal (521) 521
cohort studies (494) 494
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (490) 490
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10638) 10638
Japanese (112) 112
German (87) 87
Spanish (81) 81
Russian (69) 69
French (50) 50
Hungarian (32) 32
Italian (29) 29
Polish (20) 20
Chinese (18) 18
Czech (12) 12
Dutch (12) 12
Swedish (12) 12
Norwegian (11) 11
Portuguese (10) 10
Turkish (9) 9
Ukrainian (9) 9
Danish (7) 7
Finnish (7) 7
Hebrew (4) 4
Croatian (3) 3
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hypertension, ISSN 0194-911X, 08/2007, Volume 50, Issue 2, pp. 377 - 383
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 25, pp. 2387 - 2397
Journal Article
Experimental Eye Research, ISSN 0014-4835, 2009, Volume 89, Issue 1, pp. 71 - 78
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are frequently used lipid-lowering drugs in type 2 diabetes... 
blood–retina barrier | statin | diabetic retinopathy | inflammation | tight junction | blood-retina barrier | INTERCELLULAR-ADHESION MOLECULE-1 | EPITHELIUM-DERIVED FACTOR | MACULAR EDEMA | IN-VIVO | OPHTHALMOLOGY | RETINOPATHY | LEUKOCYTE ADHESION | TNF-ALPHA | MONOCYTE CHEMOTACTIC PROTEIN-1 | SIMVASTATIN | ENDOTHELIAL GROWTH-FACTOR | Tumor Necrosis Factor-alpha - metabolism | Retina - metabolism | Lovastatin - pharmacology | Male | NF-kappa B - metabolism | Diabetes Mellitus, Type 2 - metabolism | Blood-Retinal Barrier - drug effects | Diabetic Retinopathy - physiopathology | Lipids - blood | Inflammation Mediators - metabolism | Diabetes Mellitus, Experimental - metabolism | Diabetes Mellitus, Experimental - physiopathology | Retinal Pigment Epithelium - drug effects | Tight Junctions - drug effects | Lovastatin - therapeutic use | Drug Evaluation, Preclinical - methods | Mice, Inbred C57BL | Cells, Cultured | Diabetic Retinopathy - metabolism | Tumor Necrosis Factor-alpha - pharmacology | Diabetic Retinopathy - prevention & control | Intercellular Adhesion Molecule-1 - metabolism | Animals | Diabetes Mellitus, Type 2 - physiopathology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mice | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Type 2 diabetes | Diabetic retinopathy | Inflammation | Ophthalmology | Permeability | Statins
Journal Article
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 130, Issue 1, pp. 27 - 34
.... There is no approved treatment, but starting in 2007, several recent single-arm clinical trials administered inhibitors of protein farnesylation aimed at reducing toxicity of the disease-producing protein progerin... 
Prenylation | Lonafarnib | Progeria | Atherosclerosis | Aging | Lamins | Kaplan-Meier estimate | atherosclerosis | SYNDROME MUTATION | LONG-TERM | FARNESYLTRANSFERASE INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | lamins | PROTEIN | lonafarnib | PHENOTYPE | progeria | ZOLEDRONIC ACID | MOUSE MODEL | DISEASE | prenylation | PERIPHERAL VASCULAR DISEASE | aging | OF-THE-LITERATURE | MUTANT LAMIN-A | Atherosclerosis - genetics | Humans | Alkyl and Aryl Transferases - antagonists & inhibitors | Child, Preschool | Male | Young Adult | Piperidines - pharmacology | Nuclear Proteins - deficiency | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Child | Pravastatin - therapeutic use | Multicenter Studies as Topic - statistics & numerical data | Piperidines - administration & dosage | Progeria - mortality | Pyridines - administration & dosage | Lamin Type A | Genotype | Diphosphonates - administration & dosage | Imidazoles - pharmacology | Protein Precursors - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pravastatin - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Progeria - complications | Cohort Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Clinical Trials as Topic - statistics & numerical data | Imidazoles - administration & dosage | Cause of Death | Progeria - drug therapy | Atherosclerosis - etiology | Genes, Dominant | Adult | Female | Drug Therapy, Combination | Nuclear Proteins - genetics | Pyridines - therapeutic use | Pravastatin - pharmacology | Protein Prenylation - drug effects | Protein Precursors - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Nuclear Proteins - metabolism | Treatment Outcome | Protein Precursors - deficiency | Piperidines - therapeutic use | Dimethylallyltranstransferase - antagonists & inhibitors | Pyridines - pharmacology | Atherosclerosis - prevention & control | Diphosphonates - pharmacology | Care and treatment | Usage | Enzyme inhibitors | Patient outcomes | Genetic aspects | Health aspects | Index Medicus | Abridged Index Medicus | farnesylation | lamin | Hutchinson-Gilford progeria syndrome | FTI
Journal Article
Nature (London), ISSN 1476-4687, 2002, Volume 420, Issue 6911, pp. 78 - 84
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may also be beneficial in the treatment of inflammatory diseases. Atorvastatin (Lipitor... 
LOVASTATIN | II TRANSACTIVATOR GENE | MULTIPLE-SCLEROSIS | MICROGLIA | MULTIDISCIPLINARY SCIENCES | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | CD4(+) | EXPRESSION | STATINS | ASTROCYTES | T-CELLS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Phosphorylation | Gene Expression - drug effects | Paralysis - drug therapy | Central Nervous System Diseases - complications | Cytokines - analysis | Heptanoic Acids - therapeutic use | Encephalomyelitis, Autoimmune, Experimental - immunology | Molecular Sequence Data | Th2 Cells - immunology | Adoptive Transfer | RNA, Messenger - metabolism | Th2 Cells - drug effects | STAT6 Transcription Factor | DNA-Binding Proteins - metabolism | Microglia - immunology | STAT4 Transcription Factor | Pyrroles - administration & dosage | Trans-Activators - genetics | Heptanoic Acids - administration & dosage | Female | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Macrophages - immunology | Cytokines - immunology | Amino Acid Sequence | Microglia - drug effects | Antigen-Presenting Cells - drug effects | Encephalomyelitis, Autoimmune, Experimental - drug therapy | RNA, Messenger - genetics | Central Nervous System Diseases - immunology | Th2 Cells - cytology | Antigen-Presenting Cells - immunology | Cell Division - drug effects | Nuclear Proteins | Paralysis - complications | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Encephalomyelitis, Autoimmune, Experimental - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Central Nervous System Diseases - drug therapy | Multiple Sclerosis - immunology | Macrophages - drug effects | Trans-Activators - metabolism | Mice | Multiple Sclerosis - drug therapy | Enzymes | Nervous system | Paralysis | Disease | Immune system
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 1532-6535, 2006, Volume 81, Issue 2, pp. 194 - 204
.... Here, we investigate the effect of a model hepatic transporter inhibitor, rifampin, on the kinetics of atorvastatin and its metabolites in humans... 
ORGANIC ANION TRANSPORTER | COA REDUCTASE INHIBITOR | IN-VITRO | MAJOR DETERMINANT | MEDIATED HEPATIC-UPTAKE | PHARMACOLOGY & PHARMACY | HUMAN LIVER | CLINICAL PHARMACOKINETICS | SINGLE NUCLEOTIDE POLYMORPHISMS | DRUG-DRUG INTERACTION | P-GLYCOPROTEIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - metabolism | Rifampin - pharmacokinetics | Liver - enzymology | Pyrroles - pharmacokinetics | Tablets | Area Under Curve | Bile - chemistry | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Substrate Specificity | Bile - metabolism | Male | Enzyme Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Transfection | Enzyme Inhibitors - pharmacokinetics | Liver - drug effects | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Biological Transport - drug effects | Rifampin - administration & dosage | Binding, Competitive | Cell Line | Pyrroles - metabolism | Organic Anion Transporters - antagonists & inhibitors | Enzyme Inhibitors - metabolism | Administration, Oral | Cross-Over Studies | Organic Anion Transporters - physiology | Adolescent | Atorvastatin | Bile - drug effects | Liver-Specific Organic Anion Transporter 1 | Infusions, Intravenous | Rifampin - metabolism
Journal Article